Philip Morris International Inc (PM) Earnings

Philip Morris International Inc

PM · NYSE

Sep 2026upcoming

Next quarter

Consensus is $2.24 EPS for Sep 2026 across 4 estimates, ranging $2.23 to $2.26.

PM Jun 2026

Reported Jul 22, 2026

Beat 7.84%

EPS estimate: $2.04
EPS actual: $2.20
Revenue estimate: —
Revenue actual: —
1-day move: -1.64%

Call highlights have not been generated for this quarter.

Symbol: PM
Type: Stock
Sector: Health Care
Industry: Medicinal Chemicals and Botanical Products
Country: North America
Exchange: NYSE

Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 43% of PMI's first-quarter 2026 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes.

Key Issues

Bullish view

Philip Morris appeared in 27 of the 51 latest 13F filings reviewed for the June 30, 2026 reporting period, indicating that the stock remains widely held among recently reporting funds.

Bearish view

The 27-fund count does not show position sizes, purchases, sales, or conviction, and therefore cannot establish that institutions are becoming more bullish on PM.

Analyst Consensus

See all

Buy

15 analysts

$189

Current

—

Low

$211

Average

—

High

Average target implies +11.46% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Novartis AGNVS · NYSE$154.50